Testosterone Therapy for Men: How Dosing and Formulation Are Individualized
This educational article uses the historical URL associated with this topic: `/journal/medical-spa-lutz-tampa-men-say-same-thing/`. The URL is not a recommendation that weekly injections are inadequate, and it should not be read as a treatment conclusion.
Testosterone therapy is prescription medical treatment for selected men with appropriately diagnosed hypogonadism. It is not a treatment for ordinary aging, a general energy or performance enhancer, or a universal answer to fatigue, weight change, low motivation, or changes in body composition.
Table of Contents
- What Testosterone Therapy Can and Cannot Address
- How Hypogonadism Is Diagnosed
- Why Weekly Injections Are Not Universally Inadequate
- Choosing a Formulation and Dosing Plan
- Reversible Contributors and Obesity
- Fertility and Testosterone Therapy
- Monitoring Hematocrit and Prostate Health
- What Individualized Care Involves
- Sources
What Testosterone Therapy Can and Cannot Address
Testosterone therapy may be considered when a man has symptoms or signs consistent with testosterone deficiency and consistently low testosterone confirmed with appropriately collected testing. A clinician must also assess the likely cause and whether the potential benefits outweigh the risks.
Symptoms that can occur with low testosterone—including reduced sexual desire, erectile concerns, loss of energy, depressed mood, reduced muscle mass, or anemia—are not specific to hypogonadism. Sleep disorders, depression, medications, chronic illness, nutritional problems, relationship or life stress, and other endocrine conditions can produce similar concerns.
Testosterone is not an FDA-approved anti-aging, weight-loss, athletic performance, or longevity treatment. Normal aging by itself is not a diagnosis of hypogonadism and is not, by itself, an indication for testosterone therapy. Treatment goals should be clinical and individualized rather than based on chasing the highest laboratory value or promising more energy, confidence, sexual function, or muscle.
How Hypogonadism Is Diagnosed
Diagnosis requires compatible symptoms or signs together with unequivocally and consistently low testosterone concentrations. One borderline or unexpected result does not establish the diagnosis.
Testing is generally interpreted in clinical context and should be collected appropriately, often with a morning total testosterone measurement repeated when needed. The clinician may consider free testosterone when appropriate, assay quality, reference ranges, medications, sleep, weight, acute illness, and other relevant findings.
After low testosterone is confirmed, additional evaluation may help distinguish different causes. Depending on the history and examination, this can include review of pituitary or testicular conditions, medication effects, chronic illness, sleep disorders, and other reversible contributors. Symptoms alone do not diagnose hypogonadism, and a broad “optimization” panel is not a substitute for a clinical question.
Why Weekly Injections Are Not Universally Inadequate
The historical title of this article implied that weekly injections are not enough. That conclusion is too broad. A weekly schedule may be appropriate for some patients and products, while another schedule or formulation may be reasonable for a different patient. Pharmacokinetics, formulation, dose, injection technique, timing of laboratory testing, symptoms, adverse effects, access, and adherence all matter.
Some injectable preparations can produce higher and lower concentrations over their dosing interval. A patient who notices symptoms that appear to vary with the interval should discuss the pattern with the prescribing clinician. The right response is not automatically to inject more often, increase the dose, or switch products. A clinician should first confirm the diagnosis, review the actual medication and schedule, interpret testing at an appropriate time, and consider other causes of the symptoms.
There is no universal injection frequency or dosing protocol that is suitable for every man. Patients should not split, shorten, increase, or otherwise change a prescribed regimen based on an online article.
Choosing a Formulation and Dosing Plan
Clinician-directed options may include approved injectable, transdermal, oral, or other formulations when appropriate for the individual and available in the patient’s setting. Each option has practical considerations, potential adverse effects, and product-specific instructions. Formulations are not automatically equivalent or interchangeable.
The treatment discussion may include:
- The reason for treatment and the evidence that the diagnosis is established
- The expected goals and limitations of therapy
- Route, formulation, dose, and how the plan will be evaluated
- Symptoms, laboratory results, medical history, and other medications
- Injection or application burden, cost, access, and adherence
- Fertility goals and whether treatment may interfere with them
- Potential adverse effects and when to contact the care team
Compounded hormones should not be presented as safer, more effective, or superior because they are described as “bioidentical.” Compounded drugs are not FDA-approved and do not undergo FDA premarket review for safety, effectiveness, and quality in the same way as FDA-approved products. “Bioidentical” describes a molecular relationship; it does not, by itself, identify whether a product is FDA-approved or compounded.
Reversible Contributors and Obesity
Before or alongside treatment, a clinician may look for contributors that can be addressed without testosterone therapy. These may include inadequate sleep or untreated sleep apnea, medication effects, acute or chronic illness, depression or other mental-health conditions, nutritional concerns, excessive alcohol use, and changes in weight or activity.
Obesity can be associated with lower testosterone measurements and symptoms, but that does not mean every man with obesity needs testosterone therapy. When obesity-associated low testosterone is present without another identified cause, addressing weight and metabolic health may be an important first step. Testosterone should not be marketed as an obesity treatment or as a way to produce guaranteed weight loss.
Fertility and Testosterone Therapy
Exogenous testosterone suppresses the body’s signaling to the testes and can reduce sperm production. A man who is trying to conceive now or may want biological children should discuss fertility before starting treatment.
Testosterone should not be started casually when fertility is an active goal. A reproductive-health evaluation may be appropriate, and fertility-preserving options—if any—depend on the diagnosis and clinical situation. Products such as human chorionic gonadotropin or selective estrogen receptor modulators should not be described as automatic “support” medications or as guaranteed ways to prevent testicular changes or preserve fertility. Their use requires separate clinician assessment, and some uses may be off-label.
Monitoring Hematocrit and Prostate Health
If testosterone therapy is prescribed, follow-up is part of treatment. Monitoring is individualized and may include symptoms, testosterone concentrations interpreted in relation to the product and timing, hemoglobin and hematocrit, blood pressure, adverse effects, and other tests when clinically indicated.
Testosterone can increase red blood cell production. An elevated hematocrit or polycythemia can increase concern for complications and may require reassessment of the diagnosis, dose, formulation, contributing conditions, or whether treatment should continue. Patients should ask how this risk will be monitored rather than relying on a fixed online schedule.
Prostate evaluation should be based on age, risk factors, symptoms, shared decision-making, and applicable clinical guidance. Testosterone therapy should not be described as causing prostate cancer, and it should not be described as proven harmless in every prostate-risk scenario. Men with relevant prostate history or urinary symptoms should discuss evaluation before and during treatment. The prescribing clinician determines what monitoring is appropriate.
What Individualized Care Involves
Responsible testosterone care begins with a medical evaluation, not a promise that a particular schedule will eliminate a “crash.” A clinician reviews the patient’s symptoms, examination, repeat laboratory results, medical history, medications, sleep, weight and metabolic health, fertility plans, and individual risk factors.
If treatment is appropriate, the clinician and patient can choose a formulation and dosing plan together, explain what improvement would reasonably look like, and establish how benefits, adverse effects, and laboratory findings will be reviewed. If symptoms do not improve, the answer may be to reconsider the diagnosis or another contributor rather than simply increasing testosterone.
REJUV Timeless Health & Aesthetics provides individualized evaluation and medical guidance for appropriate patients. Learn more about men’s hormone optimization. The service page does not replace a diagnostic evaluation or determine whether testosterone therapy is appropriate for a particular person.
Sources
- Endocrine Society, Testosterone Therapy in Men With Hypogonadism Clinical Practice Guideline.
- Endocrine Society, Statement on Testosterone Replacement Therapy.
- American Urological Association, Evaluation and Management of Testosterone Deficiency Guideline.
- U.S. Food and Drug Administration, Testosterone Information.
- U.S. Food and Drug Administration, Compounding and the FDA: Questions and Answers.
This article is for general educational purposes and is not medical advice, diagnosis, or treatment. Do not start, stop, or change testosterone or any other medication based on this article. A qualified healthcare professional must determine whether evaluation or treatment is appropriate.